<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eighteen patients aged 60-84 years with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> were treated with low-dose combination chemotherapy comprising <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, and mitozantrone or 6-thioguanine; seven of these patients had a pre-existing <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Nine patients achieved a complete remission, and five had a partial remission </plain></SENT>
<SENT sid="2" pm="."><plain>The duration of survival in these 14 responding patients has ranged from 2+ to 19+ months </plain></SENT>
<SENT sid="3" pm="."><plain>Myelotoxicity occurred regularly, with time to recovery (neutrophils &gt; or =0.5 x 10(9)/L, platelets &gt; or =50 x 10(9)/L) from nadir being 10-14 days in 12 of the 14 patients </plain></SENT>
<SENT sid="4" pm="."><plain>This novel approach with an overall response rate of 78% appears to be a simple and effective form of therapy for elderly patients </plain></SENT>
</text></document>